Why This Beaten-Down Growth Stock Is a No-Brainer Buy on the Dip
The medicine hit its primary endpoint of a decrease in the average daily leg pain intensity as measured by the Numeric Pain ...
Yahoo Finance6d
Vertex Secures FDA Approval for New Cystic Fibrosis Drug Alyftrek
Vertex Pharmaceuticals VRTX announced that the FDA has approved its next-in-class vanza triple therapy for treating people with cystic fibrosis (CF) aged six years and above. The drug will be marketed ...
pharmaphorum6d
FDA approves flurry of drugs ahead of holiday season
The task ahead of Vertex now is to migrate patients already on Trikafta to the new drug. That is supported by data from the ...
Vertex Pharmaceuticals price target lowered to $460 from $550 at Truist
Truist analyst Joon Lee lowered the firm’s price target on Vertex Pharmaceuticals (VRTX) to $460 from $550 and keeps a Buy ...
3 No-Brainer Stocks to Buy on the Latest Sell-Off
We're seeing such opportunities in the market right now. Here are three no-brainer stocks to buy during the latest sell-off.
Nasdaq4d
The Zacks Analyst Blog Highlights T-Mobile, Toyota Motor, Vertex Pharmaceuticals, BK Technologies and Servotronics
Vertex is preparing for two potential near-term launches — suzetrigine in acute pain and vanza triple in CF in 2025. Vanza triple was approved as Alyftrek in December. It is rapidly progressing ...